About the Company
Cytori Cell TherapyTM is under evaluation in the United States for treatment of patients with hand and finger involvement due to the autoimmune condition scleroderma, as well as patients with symptomatic knee osteoarthritis. Our technology is approved in many countries around the world, and we have a number of active global partnerships with academic hospitals, companies and government agencies that share our interest in bringing Cytori Cell TherapyTM to patients in need.
Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma
Statistical significance not achieved in primary or secondary efficacy endpoints Clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup No significant safety related issues Conference call scheduled for 8:30am EDT SAN DIEGO,...
American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) announced today that the American Medical Association’s (AMA) CPT® (Current Procedural Terminology) Editorial Panel has approved the company’s request to add two new Category III CPT codes...
Strengthens Global Scleroderma Intellectual Property Portfolio Extends E.U. protection through 2034 SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property...
Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America
SAN DIEGO, June 14, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”), announces its new managed access program partnership with myTomorrows at the European League Against Rheumatism (EULAR) Congress in Madrid, Spain between June 14...